Early Detection Research Network


This biomarker is also known as:
  • Serine Peptidase Inhibitor, Kazal Type 1,
  • PCTT,
  • TCP,
  • Serine Protease Inhibitor, Kazal Type 1,
  • TATI,
  • SPINK1,
  • Tumor-Associated Trypsin Inhibitor,
  • Serine Protease Inhibitor, Kazal-Type 1,
  • PSTI,
  • Spink3,
  • Pancreatic Secretory Trypsin Inhibitor,


SPINK1 is a trypsin inhibitor, which is secreted from pancreatic acinar cells into pancreatic juice. Its physiological function is to prevent the trypsin-catalyzed premature activation of zymogens within the pancreas. Mutations in SPINK1 are associated with hereditary pancreatitis and tropical calcific pancreatitis.


There are no datasets associated with this biomarker.

QA State: Curated
Type: Gene

The following organs have data associated with this biomarker…


Phase: Two
QA State: Curated


High levels of SPINK1 have been associated with a greater rate of prostate cancer recurrence.

Performance Comment

Increased SPINK1 transcript expression can be a predictor of prostate cancer. A multiplexed model including seven biomarkers (AMACR, ERG, GOLPH2, PCA3, SPINK1, TFF3, TMPRSS2:ERG) outperforms serum PSA or PCA3 alone.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.